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Background: The recent emergence and rapid global spread of coronavirus disease
2019 (COVID-19) is leading to public health crises worldwide. Alcohol consumption
and cigarette smoking (CS) are two known risk factors in many diseases including
respiratory infections.
Methods: We performed a multi-center study in the four largest hospitals designated for
COVID-19 patients in Wuhan. There are totally 1547 patients diagnosed with COVID-19
enrolled in the study, alcohol consumption and CS history were evaluated among these
patients. The epidemiology, laboratory findings and outcomes of patients contracted
COVID-19 were further studied.
Results: Our findings indicated that COVID-19 patients with a history of CS tend to have
more severe outcomes than non-smoking patients. However, alcohol consumption did
not reveal significant effects on neither development of severe illness nor death rates in
COVID-19 patients.
Conclusion: CS is a risk factor for developing severe illness and increasing mortality
during the SARS-CoV-2 infection. We believe that our findings will provide a better
understanding on the effects of alcohol intake and CS exposure in COVID-19 patients.
Keywords: cigarette, alcohol, COVID-19, SARS-CoV-2, severity, death

INTRODUCTION
The recent emergence and rapid global spread of Severe Acute Respiratory Syndrome
(SARS) Coronavirus 2 (SARS-CoV-2) and the resulting coronavirus disease 2019 (COVID19) is associated with more than 12,077,210 cases and more than 550,327 deaths worldwide
as of July 9, 2020 (COVID-19 Map from Johns Hopkins Coronavirus Resource Center).
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(2020) suggested that smoking increases the risk of developing
severe COVID-19; however, another meta-analysis demonstrated
that active smoking is not associated with enhanced risk
in the progressing to severe COVID-19 (Lippi and Henry,
2020). There even are data indicate that smoking might
have protective properties against SARS-CoV-2 (Farsalinos
et al., 2020b; van Zyl-Smit et al., 2020). The challenge of
studies focused on smoking and COVID-19 is that most
hospitalized patients have underlying medical conditions such
as hypertension, diabetes, cardiovascular disease and chronic
obstructive pulmonary disease (COPD).

Considering the high rate of SARS-CoV-2 transmission and that
there is no known cure for this disease at present, identifying
vulnerable populations will be crucial for taking measures to
protect those who are at increased risk of infection or of severe
disease from COVID-19 (Clark et al., 2020).
Alcohol consumption and cigarette smoking (CS) are two
known risk factors in many diseases including respiratory
infections (Traphagen et al., 2015; Han et al., 2019). Chronic
alcohol consumption has been identified as an important
risk factor for the development of acute respiratory distress
syndrome (ARDS) (Moss et al., 2003), which is one of the
most severe complications of COVID-19. CS has been wellrecognized as a high-risk factor for respiratory diseases; however,
there is still no evidence indicating that it increases the risk
of SARS-CoV-2 infection. Even though there are numerous
studies focused on the link between smoking and COVID19, it is still unclear whether CS increases the severity of
COVID-19. A meta-analysis conducted by Vardavas and Nikitara

MATERIALS AND METHODS
Study Design and Participants
Our multi-center study was performed in the four largest
hospitals designated for COVID-19 patients in Wuhan. All

TABLE 1 | Characteristics of patients with COVID-19 with and without smoking history and alcohol consumption.
Characteristics

Age (years)

Total (n = 1547)

57.31 ± 16.09

Smoking history
Yes (n = 145)

No (n = 1429)

56.57 ± 15.89

57.39 ± 16.11

P-valuea

0.559

Alcohol consumption
Yes (n = 54)

No (n = 1493)

60.39 ± 10.68

57.17 ± 16.24

<0.001

Sex

P-valueb

0.037
<0.001

Female

745 (48.16%)

18 (12.41%)

727 (51.85%)

6 (11.11)

739 (49.56)

Male

802 (51.84%)

127 (87.59%)

675 (48.15%)

48 (88.89)

752 (50.44)

BMI

24.03 ± 3.22

23.96 ± 2.97

24.04 ± 3.25

0.866

24.12 ± 2.21

24.02 ± 3.27

0.820

54 (3.5)

25 (16.7)

29 (2.1)

<0.001

25 (46.30)

125 (8.38)

<0.001

Hypertension

423 (27.34%)

43 (29.66%)

380 (27.10%)

0.512

21 (38.89)

400 (26.83)

0.051

Diabetes

200 (12.93%)

23 (15.86%)

177 (12.62%)

0.269

12 (22.22)

186 (12.47)

0.035

Cardiovascular disease

169 (10.92%)

17 (11.72%)

17 (11.72%)

0.746

8 (14.81)

160 (10.73)

0.344

Cerebrovascular disease

40 (2.59%)

4 (2.76%)

36 (2.57%)

0.890

8 (14.81)

160 (10.73)

0.548

Carcinoma

42 (2.71%)

4 (2.76%)

38 (2.71%)

0.973

2 (3.70)

40 (2.68)

0.650

Chronic lung disease

61 (3.94%)

9 (6.21%)

52 (3.71%)

0.141

2 (3.70)

57 (3.82)

0.964

Fever

487 (31.48%)

65 (44.83%)

489 (34.20%)

0.256

15 (27.78)

470 (31.52)

0.560

Cough

282 (18.23%)

24 (16.55%)

258 (18.40%)

0.583

5 (9.26)

276 (18.51)

0.083

42 (2.71%)

6 (4.14%)

36 (2.57%)

0.268

1 (1.85)

41 (2.75)

0.690

Myalgia

160 (10.34%)

21 (14.48%)

139 (9.91%)

0.085

6 (11.11)

154 (10.33)

0.853

Diarrhea

115 (7.43%)

12 (8.28%)

103 (7.21%)

0.485

4 (7.41%)

111 (7.43%)

0.872

Shortness of breath

115 (7.43%)

9 (6.21%)

106 (7.56%)

0.554

3 (5.56)

112 (7.51)

0.591
0.432

Alcohol consumption
Comorbidities

Signs and symptoms

Expectoration

Laboratory Data
WBC, × 109 /L

7.02 (2.08,16.78)

7.23 (2.58,16.78)

6.32 (2.08,13.20)

0.133

8.84 (3.88,13.23)

7.02 (2.08,16.78)

Neutrophil count, × 109 /L

4.85 (2.89, 5.2)

5.2 (3.29, 5.2)

4.76 (2.86, 5.2)

0.480

4.72 (3.2,5.55)

4.86 (2.88, 5.2)

0.827

Lymphocyte count, × 109 /L

1.32 (0.85, 1.47)

1.08 (0.68, 1.32)

1.32 (0.88, 1.5)

<0.001

1.06 (0.65,1.32)

1.32 (0.86,1.47)

0.015

Platelet count, × 109 /L

203.8 (155, 238)

179 (127, 209)

203.8 (160, 242)

<0.001

186.5 (142,241)

203.8 (156,238)

0.196

D-dimer, mg/L

1.26 (0.4, 14.7)

1.26 (0.4, 14.7)

1.26 (0.41, 14.7)

0.967

0.92 (0.49,10.29)

1.27 (0.39, 14.7)

0.684

C-reactive protein, mg/L

9.98 (1.4, 27.59)

23.9 (3.91, 34.3)

8.39 (1.29, 27.59)

0.002

7.18 (2.13,27.59)

10.4 (1.39,27.59)

0.977

ALT, U/L

27 (16, 35.78)

25.9 (17, 40)

27.25 (16, 35.78)

0.603

30.7 (20, 52.6)

27 (16, 35.78)

0.040

AST, U/L

26 (18, 40.05)

30 (20, 43)

25.3 (18, 40.05)

0.003

31 (21, 40.05)

26 (18, 40.05)

0.128

28.67 (1.50,798.00)

45.93 (1.50,798.0)

6.52 (1.50, 496.70)

0.503

32.02 (1.50, 798.0)

6.52 (1.50, 374.12)

0.514

0.43 (0.02, 57.17)

0.56 (0.05, 57.17)

0.12 (0.02, 28.45)

0.069

0.38 (0.02, 40.08)

0.58 (0.02, 57.17)

0.103

IL-6, pg/mL
Procalcitonin, ng/mL

Data are presented as mean ± SD or n (%). Laboratory data on the day of admission were collected. a P-values indicate differences between COVID-19 patient with and
without smoking history; b COVID-19 patient with and without Alcohol consumption; P < 0.05 was considered statistically significant. BMI, body mass index; WBC, white
blood cell count; ALT, alanine transaminase; AST, aspartate transaminase.
Frontiers in Physiology | www.frontiersin.org
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hospitalized patients were confirmed COVID-19 positive
according to the interim guidance from the World Health
Organization and National Health Commission of China (World
Health Organization, 2020), from February 01 to April 10,
2020. The severe illness was defined according to the New
Coronavirus Pneumonia Prevention and Control Program (5th
edition) issued by the National Health Commission of China
(Supplementary Methods). The study was approved by the
institutional ethics review board and the need for informed
consent was waived.

Data Collection
Clinical course, laboratory findings and outcomes were
obtained and reviewed. The medical records were analyzed
by three investigators independently. Information included
demographic characteristics, symptoms, signs, underlying
comorbid conditions and treatments were collected from the
medical records. Laboratory data on the day of admission were
collected. Smoking history was defined according to the WHO
guidelines, including smoking for more than 6 months, or
smoking more than 5 or more cigarettes per day (US Department
of Health and Human Services, 2014); alcohol consumption was
defined as an average of more than 7 standard drinks per week or
more than 3 standard drinks per day (1 standard drink = 14 g of
ethanol) (Burton and Sherons, 2018).

Statistical Analysis
Categorical variables were described as frequency rates
and percentages. Continuous variables were presented as
mean ± standard deviation (SD) or mean, and interquartile
range (IQR) as appropriately. We used the Mann–Whitney U
test, x2 test, or Student’s t-test to compare differences between
two different groups where appropriate. Univariable and
multivariable logistic regression analyses were used to identify
any association between serious illness and smoking history.
Univariable and multivariable cox regression analyses were used
to identify any association between death and smoking history.
Variables with a P-value less than 0.05 at univariable analysis
were subjected to multivariable analysis, and odds ratios with
95% confidence intervals (CIs) were reported. The areas under
the receiver operating characteristic curve were used to evaluate

FIGURE 1 | Kaplan-Meier survival curves for COVID-19 patients with and
without Smoking history. *P < 0.01 for smoking group vs. non-smoking group.

TABLE 2 | Risk factors associated with severe illness by logistic regression.
Univariable analysis

Multivariable analysis

cOR

95% CI

p

aOR

95% CI

P

Age

1.052

1.043–1.062

<0.001

1.026

1.015–1.038

<0.001

Gender

1.936

1.528–2.453

<0.001

BMI

0.992

0.923–1.084

0.992

Smoking

1.955

1.375–2.779

<0.001

1.910

1.203–3.033

0.001

Alcohol consumption

1.639

0.926–2.900

0.090

Diabetes

4.313

3.168–5.871

<0.001

3.713

2.432–5.668

<0.001

Hypertension

3.151

2.468–4.024

<0.001

1.644

1.154–2.342

0.006

Chronic lung disease

3.012

1.784–5.087

<0.001

3.114

1.370–7.078

0.007

Cerebrovascular disease

4.256

2.211–8.190

<0.001
<0.001
1.192

1.123–1.264

<0.001

1.021

1.015–1.026

<0.001

1.011

1.005–1.017

<0.001

Cardiovascular disease

2.719

1.956–3.779

Carcinoma

3.393

1.831–6.287

0.001

Lymphocyte count

0.993

0.991–0.994

<0.001

Neutrophil count

1.379

1.316–1.446

<0.001

C-reactive protein

1.036

1.030–1.041

<0.001

ALT

1.010

1.006–1.014

<0.001

AST

1.027

1.021–1.032

<0.001

D-dimer

1.000

0.999–1.001

0.964

Data in parentheses are 95% confidence intervals. P < 0.05 was considered statistically significant; ALT, alanine transaminase; AST, aspartate transaminase. In the
univariate model, risk ratios were not adjusted for any confounders. In multivariate model, risk ratios were additionally adjusted for confounders with p < 0.05 in the
univariate model, and these independent variables are corrected for each other, thus obtaining the corrected partial regression coefficient (aOR/aHR).
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TABLE 3 | Risk factors associated with mortality by cox regression.
Univariable analysis

Multivariable analysis

cHR

95% CI

p

aHR

95% CI

P

Age

1.054

1.044–1.064

<0.001

1.031

1.019–1.041

<0.001

Gender

2.216

1.638–2.759

<0.001

BMI

0.984

0.912–1.061

0.671

Smoking

2.265

1.627–3.153

<0.001

1.825

1.275–2.613

0.001

Alcohol consumption

1.200

0.656–2.196

0.554
1.453

1.063–1.985

0.019

1.485

1.078–2.045

0.015

1.071

1.054–1.089

<0.001

Diabetes

2.280

1.721–3.019

<0.001

Hypertension

2.365

1.852–3.018

<0.001

Chronic lung disease

2.899

1.918–4.38

<0.001

Cerebrovascular disease

3.464

2.194–5.47

<0.001

Cardiovascular disease

2.295

1.716–3.07

<0.001

Carcinoma

2.435

1.445–4.102

0.001

Neutrophil count

1.101

1.091–1.111

<0.001

Lymphocyte count

0.309

0.238–0.400

<0.001

C-reactive protein

1.008

1.007–1.009

<0.001

1.007

1.006–1.009

<0.001

ALT

1.002

1.001–1.003

<0.001

1.001

1.000–1.002

0.010

AST

1.001

1.001–1.001

<0.001

D-dimer

1.001

1.000–1.001

0.263

Data in parentheses are 95% confidence intervals. P < 0.05 was considered statistically significant; ALT, alanine transaminase; AST, aspartate transaminase. In the
univariate model, risk ratios were not adjusted for any confounders. In multivariate model, risk ratios were additionally adjusted for confounders with p < 0.05 in the
univariate model, and these independent variables are corrected for each other, thus obtaining the corrected partial regression coefficient (aOR/aHR).

the discriminative abilities of the disease severity status. P-values
less than 0.05 were considered to indicate statistical significance.
Statistical analyses were performed by using statistical software
(SPSS version 26.0).

results revealed that the smoking groups had greater deteriorated
outcomes than the non-smoking groups (Figure 1).

Characteristics of COVID-19 Patients
With and Without Alcohol Consumption
Within the same population, two groups were divided according
to whether they had a history of alcohol consumption. The
proportion of males in the alcohol group was higher than
that in the non-alcohol group (88.89% vs. 50.44%, p < 0.001).
There was no statistically significant difference in age and
BMI. Concerning comorbidities and symptoms upon admission,
COVID-19 patients with and without alcohol consumption were
similar except for a higher proportion of diabetes (22.22% vs.
12.47%, p = 0.035). In terms of laboratory indicators, the counts
of lymphocyte from the alcohol group were lower than that of
the non-alcohol group, while ALT was higher than that of the
non-alcohol group. The difference was statistically significant
(p < 0.05, Table 1). The Odds Ratio (OR) for the effect of CS
on severe illness was 1.910 (95% CI = 1.203–3.033, p = 0.001),
indicating that the risk of severe illness in patients with previous
CS history was 1.91 times higher than that in non-smokers.

RESULTS
A total of 1547 subjects, including 802 male patients (51.8%)
and 745 female patients (48.2%), were enrolled in the study.
According to past medical history, the most common concurrent
diseases were hypertension (27.34%), diabetes (12.93%) and
cardiovascular disease (10.92%) (Supplementary Table 1).
Among 1547 patients, there are 390 severe patients (25.21%), and
257 death patients (16.61%).

Characteristics of COVID-19 Patients
With and Without Smoking History
Firstly, the population was divided into sub-groups according
to whether they had a history of smoking. In the smoking
group, the proportion of males was higher than that in the nonsmoking group (87.59% vs. 48.15%, p < 0.001). There was no
statistically significant difference in age, BMI, comorbidities and
symptoms between the smoking group and the non-smoking
group. However, in terms of biochemical indicators, the counts of
lymphocyte and thrombocyte of the smoking group were lower
than that of the non-smoking group, while C-reactive protein
and AST were higher than that of the non-smoking group.
The difference was statistically significant (all p-values < 0.05,
Table 1). To further describe the effects of smoking, we conducted
a Kaplan-Meier survival curves for COVID-19 patients. The

Frontiers in Physiology | www.frontiersin.org

Risk Factors Associated With Severe
Illness and Mortality
However, in both univariable and multivariable analyses, alcohol
consumption did not reveal any significant effect on developing
severe illness in COVID-19 patients (Table 2). Among them,
CS had a Hazard Ratios (HR) = 1.825 (95% CI = 1.275-2.613,
p = 0.001), indicating that the risk of death in smokers was 1.825
times higher than that in non-smokers. Also, lymphocyte count,
C-reactive protein, and ALT were risk factors for death. However,
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Studies have shown that smoking may increase multiple enzymes
in the human liver. Cirrhosis of the liver has a recognized
immune dysfunction status that includes immunodeficiency and
systemic inflammation, making it reasonable for those patients
to be more susceptible to SARS-CoV-2 infection (VelardeRuiz Velasco et al., 2020). In this study, the data we collected
containing a total of 1,547 patients with 150 smokers, which will
provide a better understanding of the effects of CS in COVID19. Based on our analysis, COVID-19 patients with a history of
CS had more severe outcomes when compared to the population
without a CS history.
In conclusion, CS is a risk factor for developing severe illness
and increasing mortality during the SARS-CoV-2 infection. We
believe that our findings will provide a better understanding
on the effects of alcohol intake and CS exposure in COVID19 patients.

alcohol consumption did not show a significant effect on death
rates of COVID-19 patients in both univariable and multivariable
analyses (Table 3). In this study, we analyzed the association
between alcohol consumption, CS, and the risk of COVID-19.
Our findings indicated that COVID-19 patients with a history
of CS tend to have more severe outcomes than non-smoking
patients. However, alcohol consumption did not reveal significant
effects on neither development of severe illness nor death rates in
COVID-19 patients.

DISCUSSION
Alcohol is the most commonly abused drug in the world. It
affects almost every organ of our body. At this time, patients
with a history of alcohol consumption did not develop more
severe outcomes compared to patients without. That might
be because the time we collect our data is still in the early
stage of the pandemic. With the SARS-CoV-2 rapidly spreading,
governments across the world have issued stay-at-home and
face covering orders, which resulted in trillions of people being
isolated from each other for long periods of time. Combining
with the stress of rising unemployment, excessive use of alcohol
consumption becomes a public health crisis (Clay and Parker,
2020). Several meta-analyses suggested that there is a significant
association between COVID-19 and CS; however, they also
admitted their analyses were limited by sample size and number
of primary researches (Farsalinos et al., 2020a). In our study, the
counts of lymphocyte of the smoking group were lower than
that of the non-smoking group, which may contribute to the
deteriorated outcomes. Immunosuppression caused by smoking
inhibits the effective activation of T cells, which also inhibit B
cells to proliferate and produce antibodies, thus making humoral
immunity incapable (McBride et al., 2003). C-reactive protein is
positively correlated with smoking. Increased inflammatory in
COVID-19 patients with smoking history could contribute to
the worse outcome in this subpopulation (Chen et al., 2020).
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